Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.6843 USD | -2.24% | +3.52% | -7.90% |
Business Summary
Number of employees: 55
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Difelikefalin-based Product
100.0
%
| 42 | 100.0 % | 21 | 100.0 % | -49.92% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 42 | 100.0 % | 21 | 100.0 % | -49.92% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 54 | 18-08-05 | |
Ryan Maynard
DFI | Director of Finance/CFO | 54 | 22-09-11 |
Scott Terrillion
CMP | Compliance Officer | 61 | 16-10-31 |
Iris Francesconi
IRC | Investor Relations Contact | - | - |
Beth Weinberg
LAW | General Counsel | - | - |
Richard Makara
AUD | Comptroller/Controller/Auditor | 54 | 14-09-30 |
Eric J. Vandal
PRN | Corporate Officer/Principal | - | 14-06-01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Martin Vogelbaum
CHM | Chairman | 60 | 10-06-30 |
Jeffrey Ives
BRD | Director/Board Member | 73 | 14-07-15 |
Helen Boudreau
BRD | Director/Board Member | 58 | 23-08-01 |
Chief Executive Officer | 54 | 18-08-05 | |
Susan Shiff
BRD | Director/Board Member | 63 | 20-06-25 |
Lisa von Moltke
BRD | Director/Board Member | 65 | 22-10-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 54,667,079 | 46,776,193 ( 85.57 %) | 0 | 85.57 % |
Company contact information
CARA Therapeutics, Inc.
400 Atlantic Street Suite 500
06901, Stamford
+203 406 3700
http://www.caratherapeutics.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.90% | 37.41M | |
-4.66% | 86.13B | |
+1.32% | 39.82B | |
-19.27% | 30.42B | |
+57.86% | 25.23B | |
-17.69% | 11.6B | |
-43.00% | 11.51B | |
-9.14% | 11.95B | |
+5.24% | 8.71B | |
-8.42% | 8.12B |
- Stock Market
- Equities
- CARA Stock
- Company Cara Therapeutics, Inc.